AGMB Stock Forecast & Price Target

AgomAb Therapeutics is compelling because ontunisertib has already shown a clean, GI-restricted anti-fibrotic profile in 103 FSCD patients, with no systemic ALK5 toxicity signal, 31.8% conversion of non-passable strictures to passable at 12 weeks, and placebo-adjusted endoscopic gains that support a true disease-modifying effect. The company’s lead asset addresses a large unmet need in FSCD, where no approved pharmacologic therapy exists, while the planned 2H26 OLE and NOV-ERA readouts should further de-risk efficacy, durability, and longer-term safety; meanwhile, AGMB-447 offers a second, lung-restricted ALK5 program with clean Phase 1 target engagement and additional upside. Financially, the stock appears undervalued versus peers at a roughly 14-16x discount, and pro forma cash of about €275M should fund operations into 1H29E, supporting a catalyst-rich path ahead.

AgomAb Therapeutics is a high-risk clinical-stage company with no approved drugs, so its valuation rests almost entirely on unproven assets and the possibility that early results for ontunisertib and AGMB-447 will not translate into later-stage success or regulatory approval. It also faces meaningful financing pressure, as approximately €285M in pro forma cash is still likely insufficient to support the planned ramp-up in R&D, G&A, and sales & marketing, increasing the chance of future capital raises and dilution from 2028E and 2032E onward. The outlook is further weakened by commercialization and execution risk, including dependence on CMOs, competition in FSCD, uncertain reimbursement, and the shared ALK5/TGFβR1 mechanism that could expose both programs to the same chronic safety concerns.